Búsqueda | Portal de Búsqueda de la BVS España

1.

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Freeman, Sylvie D; Thomas, Abin; Thomas, Ian; Hills, Robert K; Vyas, Paresh; Gilkes, Amanda; Metzner, Marlen; Jakobsen, Niels Asger; Kennedy, Alison; Moore, Rachel; Almuina, Nuria Marquez; Burns, Sarah; King, Sophie; Andrew, Georgia; Gallagher, Kathleen M E; Sellar, Rob S; Cahalin, Paul; Weber, Duruta; Dennis, Mike; Mehta, Priyanka; Knapper, Steven; Russell, Nigel H.

Blood; 142(20): 1697-1707, 2023 11 16.

Artículo en Inglés | MEDLINE | ID: mdl-37595359

2.

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

Copland, Mhairi; Ariti, Cono; Thomas, Ian F; Upton, Laura; Sydenham, Mia; Mehta, Priyanka; Islam, Shahid; Kjeldsen, Lars; Burnett, Alan K; Hills, Robert K; Russell, Nigel; Dennis, Mike.

Br J Haematol; 204(3): 871-876, 2024 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-38016651

3.

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.

Hills, Robert K.

Br J Haematol; 203(3): 353-354, 2023 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-37612135

4.

What drives CAR-T emergent cytopenia?

Hills, Robert K.

Br J Haematol; 202(2): 213-214, 2023 07.

Artículo en Inglés | MEDLINE | ID: mdl-37009828

5.

Therapy for isocitrate dehydrogenase 2 (IDH2)^R172 -mutant acute myeloid leukaemia.

Linch, David C; Hills, Robert K; Burnett, Alan K; Russell, Nigel; Gale, Rosemary E.

Br J Haematol; 196(6): 1348-1352, 2022 03.

Artículo en Inglés | MEDLINE | ID: mdl-34870324

6.

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.

Russell, Nigel H; Hills, Robert K; Kjeldsen, Lars; Clark, Richard E; Ali, Sahra; Cahalin, Paul; Thomas, Ian F; Burnett, Alan K.

Br J Haematol; 198(3): 528-534, 2022 08.

Artículo en Inglés | MEDLINE | ID: mdl-35388465

7.

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.

Russell, Nigel H; Hills, Robert K; Thomas, Abin; Thomas, Ian; Kjeldsen, Lars; Dennis, Mike; Craddock, Charles; Freeman, Sylvie; Clark, Richard E; Burnett, Alan K.

Haematologica; 107(7): 1518-1527, 2022 07 01.

Artículo en Inglés | MEDLINE | ID: mdl-34647442

8.

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.

Kayser, Sabine; Hills, Robert K; Langova, Ralitsa; Kramer, Michael; Guijarro, Francesca; Sustkova, Zuzana; Estey, Elihu H; Shaw, Carole M; Rácil, Zdenek; Mayer, Jiri; Zak, Pavel; Baer, Maria R; Brunner, Andrew M; Szotkowski, Tomas; Cetkovsky, Petr; Grimwade, David; Walter, Roland B; Burnett, Alan K; Ho, Anthony D; Ehninger, Gerhard; Müller-Tidow, Carsten; Platzbecker, Uwe; Thiede, Christian; Röllig, Christoph; Schulz, Angela; Warsow, Gregor; Brors, Benedikt; Esteve, Jordi; Russell, Nigel H; Schlenk, Richard F; Levis, Mark J.

Br J Haematol; 192(5): 832-842, 2021 03.

Artículo en Inglés | MEDLINE | ID: mdl-33529373

9.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Christen, Friederike; Hoyer, Kaja; Yoshida, Kenichi; Hou, Hsin-An; Waldhueter, Nils; Heuser, Michael; Hills, Robert K; Chan, Willy; Hablesreiter, Raphael; Blau, Olga; Ochi, Yotaro; Klement, Piroska; Chou, Wen-Chien; Blau, Igor-Wolfgang; Tang, Jih-Luh; Zemojtel, Tomasz; Shiraishi, Yuichi; Shiozawa, Yusuke; Thol, Felicitas; Ganser, Arnold; Löwenberg, Bob; Linch, David C; Bullinger, Lars; Valk, Peter J M; Tien, Hwei-Fang; Gale, Rosemary E; Ogawa, Seishi; Damm, Frederik.

Blood; 133(10): 1140-1151, 2019 03 07.

Artículo en Inglés | MEDLINE | ID: mdl-30610028

10.

Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.

Greiner, Jochen; Brown, Elliott; Bullinger, Lars; Hills, Robert K; Morris, Vanessa; Döhner, Hartmut; Mills, Ken I; Guinn, Barbara-Ann.

Int J Mol Sci; 22(19)2021 Sep 28.

Artículo en Inglés | MEDLINE | ID: mdl-34638823

11.

Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.

Hills, Robert K.

Br J Haematol; 188(1): 29-35, 2020 01.

Artículo en Inglés | MEDLINE | ID: mdl-31833053

12.

Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.

Linch, David C; Hills, Robert K; Burnett, Alan K; Russell, Nigel; Gale, Rosemary E.

Br J Haematol; 188(6): 852-859, 2020 03.

Artículo en Inglés | MEDLINE | ID: mdl-31595497

13.

Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.

Zabkiewicz, Joanna; Lazenby, Michelle; Edwards, Gareth; Bygrave, Ceri A; Omidvar, Nader; Zhuang, Lihui; Knapper, Steve; Guy, Carol; Hills, Robert K; Burnett, Alan K; Alvares, Caroline L.

Br J Haematol; 191(2): 231-242, 2020 10.

Artículo en Inglés | MEDLINE | ID: mdl-32394450

14.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Voisset, Edwige; Moravcsik, Eva; Stratford, Eva W; Jaye, Amie; Palgrave, Christopher J; Hills, Robert K; Salomoni, Paolo; Kogan, Scott C; Solomon, Ellen; Grimwade, David.

Blood; 131(6): 636-648, 2018 02 08.

Artículo en Inglés | MEDLINE | ID: mdl-29191918

15.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis, Gerrit J; Heuser, Michael; Freeman, Sylvie; Béné, Marie-Christine; Buccisano, Francesco; Cloos, Jacqueline; Grimwade, David; Haferlach, Torsten; Hills, Robert K; Hourigan, Christopher S; Jorgensen, Jeffrey L; Kern, Wolfgang; Lacombe, Francis; Maurillo, Luca; Preudhomme, Claude; van der Reijden, Bert A; Thiede, Christian; Venditti, Adriano; Vyas, Paresh; Wood, Brent L; Walter, Roland B; Döhner, Konstanze; Roboz, Gail J; Ossenkoppele, Gert J.

Blood; 131(12): 1275-1291, 2018 03 22.

Artículo en Inglés | MEDLINE | ID: mdl-29330221

16.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.

Kayser, Sabine; Hills, Robert K; Luskin, Marlise R; Brunner, Andrew M; Terré, Christine; Westermann, Jörg; Menghrajani, Kamal; Shaw, Carole; Baer, Maria R; Elliott, Michelle A; Perl, Alexander E; Rácil, Zdenek; Mayer, Jiri; Zak, Pavel; Szotkowski, Tomas; de Botton, Stéphane; Grimwade, David; Mayer, Karin; Walter, Roland B; Krämer, Alwin; Burnett, Alan K; Ho, Anthony D; Platzbecker, Uwe; Thiede, Christian; Ehninger, Gerhard; Stone, Richard M; Röllig, Christoph; Tallman, Martin S; Estey, Elihu H; Müller-Tidow, Carsten; Russell, Nigel H; Schlenk, Richard F; Levis, Mark J.

Haematologica; 105(1): 161-169, 2020 01.

Artículo en Inglés | MEDLINE | ID: mdl-31004014

17.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Ivey, Adam; Hills, Robert K; Simpson, Michael A; Jovanovic, Jelena V; Gilkes, Amanda; Grech, Angela; Patel, Yashma; Bhudia, Neesa; Farah, Hassan; Mason, Joanne; Wall, Kerry; Akiki, Susanna; Griffiths, Michael; Solomon, Ellen; McCaughan, Frank; Linch, David C; Gale, Rosemary E; Vyas, Paresh; Freeman, Sylvie D; Russell, Nigel; Burnett, Alan K; Grimwade, David.

N Engl J Med; 374(5): 422-33, 2016 Feb 04.

Artículo en Inglés | MEDLINE | ID: mdl-26789727

18.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Knapper, Steven; Russell, Nigel; Gilkes, Amanda; Hills, Robert K; Gale, Rosemary E; Cavenagh, James D; Jones, Gail; Kjeldsen, Lars; Grunwald, Michael R; Thomas, Ian; Konig, Heiko; Levis, Mark J; Burnett, Alan K.

Blood; 129(9): 1143-1154, 2017 03 02.

Artículo en Inglés | MEDLINE | ID: mdl-27872058

19.

Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.

El-Sharkawi, Dima; Sproul, Duncan; Allen, Christopher G; Feber, Andrew; Wright, Melissa; Hills, Robert K; Linch, David C; Gale, Rosemary E.

Haematologica; 103(1): 91-100, 2018 01.

Artículo en Inglés | MEDLINE | ID: mdl-29025912

20.

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.

Burnett, Alan K; Das Gupta, Emma; Knapper, Steve; Khwaja, Asim; Sweeney, Marion; Kjeldsen, Lars; Hawkins, Timothy; Betteridge, Sophie E; Cahalin, Paul; Clark, Richard E; Hills, Robert K; Russell, Nigel H.

Haematologica; 103(10): 1654-1661, 2018 10.

Artículo en Inglés | MEDLINE | ID: mdl-29976746

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.

What drives CAR-T emergent cytopenia?

Therapy for isocitrate dehydrogenase 2 (IDH2)^R172 -mutant acute myeloid leukaemia.

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Survivin' Acute Myeloid Leukaemia-A Personalised Target for inv(16) Patients.

Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.

Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.

Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.

Assessment of Minimal Residual Disease in Standard-Risk AML.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.